GSK: end of strategic alliance with Valneva
(CercleFinance.com) - Valneva has announced that it has agreed with GSK to terminate a strategic alliance, which will enable it to regain control of its core R&D assets, including its Lyme VLA15 vaccine candidate.
It will immediately pay GSK nine million euros and then make milestone payments depending on Lyme disease marketing authorisations, which could reach seven million euros.
The British pharmaceutical company says that this decision is part of its ongoing initiative to allocate capital to a limited number of projects focusing on its priority areas.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
It will immediately pay GSK nine million euros and then make milestone payments depending on Lyme disease marketing authorisations, which could reach seven million euros.
The British pharmaceutical company says that this decision is part of its ongoing initiative to allocate capital to a limited number of projects focusing on its priority areas.
Copyright (c) 2019 CercleFinance.com. All rights reserved.